Mar 7 |
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
|
Feb 6 |
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
|
Jan 8 |
Exagen reaffirms FY23 revenue of at least $50M
|
Jan 7 |
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
|
Nov 20 |
Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript
|
Nov 17 |
Exagen files for a $150M mixed shelf offering
|
Nov 13 |
Exagen GAAP EPS of -$0.31 beats by $0.15, revenue of $13.4M beats by $3.07M
|
Nov 13 |
Exagen Inc. Reports Strong Third Quarter 2023 Results
|
Nov 9 |
Exagen licenses lupus nephritis biomarkers from Johns Hopkins
|
Nov 9 |
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
|